Abstract
Background/objectives
To report clinical outcomes of modified Collaborative Ocular Melanoma Study IRIS (COMS IRIS) plaques for treatment of iris, iridociliary, and ciliary body melanoma.
Subjects/methods
Retrospective, single-centre cohort study of iris melanoma treated with COMS IRIS plaque radiotherapy from July 26, 2010 to October 15, 2018. Medical records were reviewed for demographics, tumour features, treatment parameters, and clinical outcomes.
Results
There were 22 cases, diagnosed at mean age of 59 years (median 65, range 21–85 years) with female sex in 14 (64%). Presenting tumour features included Snellen visual acuity (VA) ≥ 20/40 in 18 (82%) cases, mean largest tumour basal diameter 4.7 mm (median 3.9, range 2.3–13.8 mm) and thickness 1.7 mm (median 1.6 mm, range 0.8–3.9 mm), iris stromal seeding in 3 (14%) cases, angle seeding in 16 (73%), and ciliary body involvement in 13 (59%). After mean follow-up of 51 months (median 44, range 4–113 months), Snellen VA was ≥20/40 in 14 (64%) cases, with local tumour recurrence in 2 (9%), and enucleation in 2 (9%). The 3-year Kaplan–Meier estimated risk of local tumour recurrence was 7%. The most common radiation side effects were cataract in 17 (77%) patients and dry eye in 5 (23%). Systemic metastasis occurred in no cases, and 1 (5%) non-melanoma-related death due to natural causes was observed at last follow-up.
Conclusions
COMS IRIS plaques are effective for treatment of iris, iridociliary, and ciliary body melanoma with modest VA outcomes and low frequency of local tumour recurrence, enucleation, radiation side effects, and systemic metastasis.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina 2012;32:1363–72.
Jensen O. Malignant melanomas of the human uvea: recent follow‐up of cases in Denmark, 1943–1952. Acta Ophthalmol. 1970;48:1113–28.
Shields CL, Kaliki S, Shah SU, Luo W, Furuta M, Shields JA. Iris melanoma: Features and prognosis in 317 children and adults. J AAPOS. 2012;16:10–6.
Singh AD, Damato BE. Iris melanoma. Clinical Ophthalmic Oncology: Springer; 2019. p. 155–84.
Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 2001;108:172–8.
Khan S, Finger PT, Yu G-P, Razzaq L, Jager MJ, De Keizer RJ, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012;130:57–64.
Fernandes BF, Krema H, Fulda E, Pavlin CJ, Payne DG, McGowan HD, et al. Management of iris melanomas with 125Iodine plaque radiotherapy. Am J Ophthalmol. 2010;149:70–6. e2.
Razzaq L, Keunen JEE, Schalij-Delfos NE, Creutzberg CL, Ketelaars M, de Keizer RJW. Ruthenium plaque radiation therapy for iris and iridociliary melanomas. Acta Ophthalmol. 2012;90:291–6.
Shields CL, Shah SU, Bianciotto CG, Emrich J, Komarnicky L, Shields JA. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes. Ophthalmology 2013;120:55–61.
Tsimpida M, Hungerford J, Arora A, Cohen V. Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma. Eye. 2011;25:1607–11.
Yousef YA, Finger PT. Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma. Int J Radiat Oncol Biol Phys. 2012;83:1107–12.
Konstantinidis L, Roberts D, Errington RD, Kacperek A, Damato B. Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. Br J Ophthalmol. 2013;97:471–4.
Willerding GD, Cordini D, Hackl C, Karle B, Lakotka N, Foerster MH, et al. Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol. 2015;99:812.
Thomson RM, Furutani KM, Pulido JS, Stafford SL, Rogers DW. Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy. Int J Radiat Oncol Biol Phys. 2010;78:1261–9.
Amin MB, Edge SB. AJCC cancer staging manual. Springer; 2017.
Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, et al. Update of AAPM Task Group No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31:633–74.
Popovic M, Ahmed IIK, DiGiovanni J, Shields CL. Radiotherapeutic and surgical management of iris melanoma: a review. Surv Ophthalmol. 2017;62:302–11.
Finger PT. Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am J Ophthalmol. 2001;132:328–35.
Shields CL, Naseripour M, Shields JA, Freire J, Cater J. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol. 2003;135:648–56.
Chaugule SS, Finger PT. Regression patterns of iris melanoma after palladium-103 ((103)Pd) plaque brachytherapy. Ophthalmology 2017;124:1023–30.
Agraval U, Sobti M, Russell HC, Lockington D, Ritchie D, Cauchi P, et al. Use of ruthenium-106 brachytherapy for iris melanoma: the Scottish experience. Br J Ophthalmol. 2018;102:74–8.
Liu W, Kim JM, Young BK, Nath R, Chen Z, Decker RH, et al. Novel eye plaque designs for brachytherapy of iris and ciliary body melanoma and the first clinical application. Ocul Oncol Pathol. 2019;5:220–8.
Scanderbeg DJ, Vasudev D, Rice RK, Goldbaum M, Mundt AJ. A modified COMS plaque for iris melanoma. J Contemp Brachytherapy. 2011;3:131–3.
Chiu-Tsao S-T, Astrahan MA, Finger PT, Followill DS, Meigooni AS, Melhus CS, et al. Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. Med Phys. 2012;39:6161–84.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xu, T.T., Pulido, J.S., Deufel, C.L. et al. Clinical outcomes of Modified Collaborative Ocular Melanoma Study IRIS plaques for treatment of iris, iridociliary, and ciliary body melanoma. Eye 35, 2754–2762 (2021). https://doi.org/10.1038/s41433-020-01295-y
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-020-01295-y
